AU2008295145B2 - Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events - Google Patents
Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events Download PDFInfo
- Publication number
- AU2008295145B2 AU2008295145B2 AU2008295145A AU2008295145A AU2008295145B2 AU 2008295145 B2 AU2008295145 B2 AU 2008295145B2 AU 2008295145 A AU2008295145 A AU 2008295145A AU 2008295145 A AU2008295145 A AU 2008295145A AU 2008295145 B2 AU2008295145 B2 AU 2008295145B2
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- rasburicase
- prophylaxis
- uric acid
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07291072.2 | 2007-09-05 | ||
| EP07291072 | 2007-09-05 | ||
| US1524007P | 2007-12-20 | 2007-12-20 | |
| US61/015,240 | 2007-12-20 | ||
| PCT/EP2008/006858 WO2009030373A1 (en) | 2007-09-05 | 2008-08-20 | Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008295145A1 AU2008295145A1 (en) | 2009-03-12 |
| AU2008295145B2 true AU2008295145B2 (en) | 2013-12-05 |
Family
ID=38713162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008295145A Ceased AU2008295145B2 (en) | 2007-09-05 | 2008-08-20 | Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events |
Country Status (22)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114972A (en) * | 1990-07-30 | 1992-05-19 | Tsuyoshi Ohnishi | Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities |
| WO2004026118A2 (en) * | 2002-09-20 | 2004-04-01 | Oregon Health & Science University | Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries |
| WO2005077042A2 (en) * | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050232902A1 (en) * | 2004-04-17 | 2005-10-20 | Theodoros Kofidis | Injectable bioartificial tissue matrix |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1317258B1 (en) * | 2000-06-28 | 2009-02-11 | Merck & Co., Inc. | Use of allopurinol for the treatment of hypertension |
| US20070197512A1 (en) * | 2006-01-27 | 2007-08-23 | Japan Tobacco Inc. | Carboxylic Acid Compounds and Use Thereof |
-
2008
- 2008-08-20 EP EP08785655A patent/EP2197550A1/en not_active Withdrawn
- 2008-08-20 CA CA2697929A patent/CA2697929A1/en not_active Abandoned
- 2008-08-20 KR KR1020107004878A patent/KR20100053609A/ko not_active Ceased
- 2008-08-20 AU AU2008295145A patent/AU2008295145B2/en not_active Ceased
- 2008-08-20 MY MYPI2010000585A patent/MY183770A/en unknown
- 2008-08-20 BR BRPI0816406A patent/BRPI0816406A2/pt not_active IP Right Cessation
- 2008-08-20 CN CN200880105379A patent/CN101801460A/zh active Pending
- 2008-08-20 JP JP2010523299A patent/JP2011509920A/ja active Pending
- 2008-08-20 MX MX2010001976A patent/MX2010001976A/es active IP Right Grant
- 2008-08-20 WO PCT/EP2008/006858 patent/WO2009030373A1/en not_active Ceased
- 2008-08-20 NZ NZ583635A patent/NZ583635A/en not_active IP Right Cessation
- 2008-09-03 UY UY31320A patent/UY31320A1/es not_active Application Discontinuation
- 2008-09-03 PE PE2008001545A patent/PE20090642A1/es not_active Application Discontinuation
- 2008-09-03 PA PA20088794801A patent/PA8794801A1/es unknown
- 2008-09-03 TW TW097133674A patent/TW200927929A/zh unknown
- 2008-09-03 AR ARP080103828A patent/AR068360A1/es not_active Application Discontinuation
- 2008-09-04 CL CL2008002623A patent/CL2008002623A1/es unknown
-
2010
- 2010-02-02 ZA ZA2010/00774A patent/ZA201000774B/en unknown
- 2010-02-22 MA MA32638A patent/MA31624B1/fr unknown
- 2010-02-24 CO CO10021841A patent/CO6260090A2/es not_active Application Discontinuation
- 2010-03-01 US US12/715,061 patent/US20100266567A1/en not_active Abandoned
- 2010-03-02 IL IL204259A patent/IL204259A/en not_active IP Right Cessation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114972A (en) * | 1990-07-30 | 1992-05-19 | Tsuyoshi Ohnishi | Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities |
| WO2004026118A2 (en) * | 2002-09-20 | 2004-04-01 | Oregon Health & Science University | Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries |
| WO2005077042A2 (en) * | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050232902A1 (en) * | 2004-04-17 | 2005-10-20 | Theodoros Kofidis | Injectable bioartificial tissue matrix |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2010112867A (ru) | 2011-10-10 |
| IL204259A (en) | 2013-06-27 |
| PE20090642A1 (es) | 2009-06-18 |
| MA31624B1 (fr) | 2010-08-02 |
| NZ583635A (en) | 2011-06-30 |
| CO6260090A2 (es) | 2011-03-22 |
| MX2010001976A (es) | 2010-03-10 |
| EP2197550A1 (en) | 2010-06-23 |
| TW200927929A (en) | 2009-07-01 |
| UY31320A1 (es) | 2009-04-30 |
| AU2008295145A1 (en) | 2009-03-12 |
| WO2009030373A1 (en) | 2009-03-12 |
| CN101801460A (zh) | 2010-08-11 |
| BRPI0816406A2 (pt) | 2017-05-16 |
| MY183770A (en) | 2021-03-12 |
| JP2011509920A (ja) | 2011-03-31 |
| US20100266567A1 (en) | 2010-10-21 |
| CL2008002623A1 (es) | 2009-01-16 |
| KR20100053609A (ko) | 2010-05-20 |
| PA8794801A1 (es) | 2009-04-23 |
| ZA201000774B (en) | 2011-04-28 |
| CA2697929A1 (en) | 2009-03-12 |
| AR068360A1 (es) | 2009-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8852582B2 (en) | Compositions comprising glutathione reductase and oxidized glutathione | |
| JP4842247B2 (ja) | マロニル−CoA脱炭酸酵素阻害剤を用いた代謝性疾患の治療法 | |
| CA2174236C (en) | Superoxide dismutase and mimetics thereof | |
| Borges et al. | Progress towards the discovery of xanthine oxidase inhibitors | |
| M. Costa et al. | Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases | |
| Iskesen et al. | Trimetazidine reduces oxidative stress in cardiac surgery | |
| EP0908182B2 (en) | Preventives or remedies for diseases induced by hypofunction of nitric oxide synthase (nos) | |
| Belardinelli et al. | Oxidative stress, endothelial function and coenzyme Q10 | |
| RU2191005C2 (ru) | Фармацевтические композиции, содержащие производные гидроксамовой кислоты | |
| ES2295930T3 (es) | Compuestos de cianoamida utiles como inhibidores de malonil-coa descarboxilasa. | |
| Zou et al. | Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction | |
| Fouad et al. | Protective effect of carnosine against cisplatin-induced nephrotoxicity in mice | |
| Rodríguez-Graciani et al. | Association between L-OPA1 cleavage and cardiac dysfunction during ischemia-reperfusion injury in rats | |
| JP4648317B2 (ja) | マロニル−CoAデカルボキシラーゼ阻害剤として有用なピペリジン化合物 | |
| Grum et al. | Purine efflux after cardiac ischemia: relevance to allopurinol cardioprotection | |
| JP2007501232A (ja) | マロニル−CoAデカルボキシラーゼ阻害剤として有用な複素環式化合物 | |
| US20220233565A1 (en) | Reduced nicotinamideribosides for treating/preventing skeletal muscle disease | |
| CN116234563A (zh) | 抗致病治疗方法 | |
| AU2008295145A1 (en) | Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events | |
| RU2482187C2 (ru) | Применение расбуриказы для лечения или профилактики расстройств или косвенных осложнений на сердце, вызванных приступами ишемии или реперфузией | |
| CZ74199A3 (cs) | Činidlo pro zvýšení aktivity glutathionreduktasy | |
| EP1361885B1 (en) | Use of gamma-gt inhibitors for the treatment of chronic degenerative diseases | |
| Oreščanin et al. | Effect of L-arginine on the relaxation caused by sodium nitroprusside on isolated rat renal artery | |
| Fletcher et al. | Cyclosporine A induced changes to plasma and erythrocyte antioxidant defences | |
| AlIcIgüzel et al. | Effect of intravenous nitroglycerin therapy on erythrocyte antioxidant enzymes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |